Markets & Investing
Huxley Health finalizes Sintalica deal, names Bruce Linton chairman
The company also named several other new executives.
The post Huxley Health finalizes Sintalica deal, names Bruce Linton chairman appeared first on Green…
Privately owned psychedelics company Huxley Health Inc. completed its acquisition of Canadian drug discovery company Sintalica and named Bruce Linton as its new chairman.
Sintalica operates through its Italian subsidiary and is focused on using psychedelics to create treatments for neuroinflammatory disorders. Sintalica filed four provisional patents for proprietary psychedelic molecules with unique properties, improved stability and safety profiles, and enhanced bioavailability. The deal was an all-stock transaction valued at $7.2 million.
Former Canopy Growth founder and CEO Bruce Linton was named as the company’s new chairman, replacing Michael Marchese, who previously served as the company’s only director. Linton is also chair of the advisory board of Red Light Holland Corp. (CSE: TRIP).
New team
The company continued to beef up its board and C-suite with an all-male team featuring new board members Fabian Monaco, who was also the co-founder and former CEO of Gage Growth Corp., which was acquired by TerrAscend Corp. (TSX: TSND) (OTCQX: TSNDF), and investor John Di Girolamo.
Huxley named Jared Rhines as its new chief executive officer. Rhines’ experience spans clinical research, regulatory affairs, sales, marketing, and market access in multiple therapeutic areas, including rare diseases, neurology, cardiology, and critical care. He, along with five colleagues, founded INO Therapeutics, a company that was eventually acquired for $2.3 billion.
The new chief science officer is George Jackowski, who has experience clearing 25 products through the FDA and commercializing them globally, with revenues exceeding $10 billion. He holds more than 200 issued patents.
Peter Kampian was named the chief financial officer.
Together Huxley and Sintalica have raised $6 million. The company has also successfully filed more than 10 U.S. patents to protect its intellectual property portfolio, including candidates undergoing pre-clinical testing.
The post Huxley Health finalizes Sintalica deal, names Bruce Linton chairman appeared first on Green Market Report.
psychedelics psychedelic tsx cse deal fda research-
Psilocybin7 days ago
The Psychedelic Scene in Oaxaca, Mexico
-
Law & Regulation4 days ago
FDA to weigh safety, impact of MDMA therapy for PTSD at June meeting
-
Psychedelics5 days ago
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support
-
Psychedelics1 week ago
MindBio Therapeutics Scientists Present Landmark Women’s Health Trials, Company to Release Phase 2A Depression Trial Secondary Data This Month
-
Psychedelics5 days ago
MindMed Reports First Quarter 2024 Financial Results and Business Updates
-
Psychedelics1 week ago
PharmAla Launches Prescriber’s Portal for Medical Professionals Focused on MDMA Therapy
-
Psychedelics6 days ago
Oprah Daily’s Comprehensive Guide to Psychedelics: A Milestone for Industry Acceptance
-
Psychedelics1 week ago
Lophos Pharmaceuticals Corp. Enters Into Letter of Intent to Acquire the Assets of Magicactus.com